Eton Pharmaceutcials (ETON) Stock: Buy, Sell, or Hold?
ETON - Eton Pharmaceutcials, Inc. Common Stock
$57.08
-0.80 (-1.38%)
âŧ
5d:
-4.71%
30d:
+37.28%
90d:
+77.76%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Nov 05, 2026
Get Alerted When ETON Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: ETON is fairly priced but lacks strong directional signals. At 7.2% expected growth, valuation appears stretched. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: ETON is fairly priced but lacks strong directional signals. At 7.2% expected growth, valuation appears stretched. Wait for clearer setup or better entry on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$89.93
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$55.84
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 17.9x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ETON is currently trading at $57.08, which is considered fair relative to its 30-day fair value range of $48.02 to $63.86. From a valuation perspective, the stock is trading at a premium (Forward PE: 22.1) compared to its historical average (17.9). At these levels, the market is pricing in 7.2% annual earnings growth.
Technical Outlook: Technically, ETON is in a strong uptrend. The price is currently testing key support at $56.11. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: ETON scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $71.00 (+24.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ETON is in a strong uptrend. The price is currently testing key support at $56.11. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: ETON scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $71.00 (+24.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$48.02 -
$63.86
Company Quality Score
43/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
62.3%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 0th percentile)
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 24.4% below Wall St target ($71.00)
- BULLISH: Expecting earnings turnaround to 7.2% growth with 98.6% revenue growth
- WARNING: Composite score 43/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$48.02 -
$63.86
Current vs Trading Range
FAIR
Expected Move (7 Days)
Âą$5.28
(9.2%)
Support & Resistance Levels
Support Level
$56.11
Resistance Level
$62.91
Current Trend
Strong Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
22.12
Wall Street Target
$71.00
(+24.4%)
Revenue Growth (YoY)
98.6%
Earnings Growth (YoY)
-12.6%
Profit Margin
12.0%
Valuation Premium vs History
+7.2% premium
PE vs Historical
22.1 vs 17.9
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+7.2%
(market-implied from PE analysis)
1-Year Target
$61.19
(+7%)
2-Year Target
$65.60
(+15%)
3-Year Target
$70.32
(+23%)
3-Yr Target (if PE normalizes)
(PE: 22â18)
PE COMPRESSION
$56.89
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.1, Growth: 84.3%)
$192.64
(+238%)
Base:
(SPY PE: 20.2, Growth: 84.3%)
$175.63
(+208%)
Bear:
(PE: 17.1, Growth: 84.3%)
$149.29
(+162%)
đ
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (25x PE), but valuation improves significantly next year (22x PE) as earnings recover.
Forward PE: 25.32 | Forward EPS (Implied): $2.25
Bull Case
$68.92
(+21%)
Analyst growth 15.0%, PE expands to 26.6
Base Case
$57.08
(0%)
Market implied 0.0%, PE stable at 25.3
Bear Case
$43.67
(-24%)
Severe decline -15.0%, PE contracts to 22.8
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: September 12, 2026 9:03 AM ET
Data refreshes hourly during market hours. Next update: 10:03 AM
Data refreshes hourly during market hours. Next update: 10:03 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ETON showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences IâĻ |
STRONG BUY
25 analysts |
$212 | 60 HOLD |
|
LQDA
Liquidia Technologies Inc |
STRONG BUY
10 analysts |
$108 | 70 BUY |
|
INDV
Indivior PLC Ordinary ShâĻ |
STRONG BUY
7 analysts |
$49 | 69 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$108 | 46 HOLD |
|
UTHR
United Therapeutics CorpâĻ |
STRONG BUY
15 analysts |
$664 | 47 HOLD |
